Camber Pharmaceuticals, Inc. today gained approval to market acyclovir via its ANDA215669, a move expected to bolster generic competition and potentially support maintained margins in the oral antiviral market. This supplemental approval signals the manufacturer’s continued push to capitalize on demand within the established pharmaceutical subsector.